Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Panel of International Experts Deem MR DSC Perfusion as Most Clinically Validated
MILWAUKEE, WI / ACCESSWIRE / March 7, 2022 / Imaging Biometrics, LLC (IB), a subsidiary of IQ-AI Limited, (OTCQB:IQAIF) (LSE:IQAI), is pleased to announce the publication of a review authored by International scientists about the use of advanced MRI techniques in Europe.
The paper, published in Frontiers in Oncology, was written by a team of clinicians, engineers, and physicists working on behalf of the European Cooperation in Science and Technology (COST) Glioma MR Imaging 2.0 (GLiMR) Initiative. It consisted of a comprehensive review of advanced MRI techniques used in Europe for monitoring treatment response in high-grade brain tumors. The authors of the study concluded that dynamic susceptibility contrast (DSC) MRI is the most proven of all advanced methods. IB's software modules, IB Neuro™ and IB DCE™, provided solutions for analysis of this data, with examples from each included in the paper.
The study acknowledged the limitations and challenges presented with conventional MRI and specifically noted the quantitative technology contained in IB Neuro termed "standardization." This exclusive technology is built into IB Neuro and automatically generates standardized relative cerebral blood volume (sRCBV) maps. And, as the paper cites, IB Neuro's sRCBV has demonstrated greater consistency and improved repeatability over the inherently variable and manual "tissue normalization" approaches.
"Standardization is significant because it allows for direct comparison between scans independent of MR scanner platform, field strength, or patient," said Michael Schmainda, CEO of IB. "This paper nicely summarizes the advancements made over the years in advanced MRI techniques, and we are pleased that the sRCBV technology available in IB Neuro was highlighted."
https://twitter.com/AccesswireNews/status/1500844205819760641
More to come.
The Subscription is made by a private equity professional based in New York City. This investment is part of a larger investment related to his family's Family Office which is anticipated to subscribe to a further US$2.025m on the same terms, for which the documentation is currently in process (the "Additional Subscriptions").
TINTRA PLC
("Tintra", the "Group" or the "Company")
Further Strategic Investment Under Funding Round
The board of directors of Tintra (the "Board") is pleased to announce that further to the announcement of 26 November 2021, that it has finalised a further subscription under the current funding round, raising a further US$250,000 (the "Subscription").
The Subscription is for 37,128 new ordinary shares of 1 pence each in the capital of the Company ("Ordinary Shares"), priced at 504 pence per Ordinary Share, at an exchange rate of £1.00:$1.336 (the "Subscription Price").
For each new Ordinary Share purchased under the Subscription, the investor will receive two warrants to subscribe for new Ordinary Shares at an exercise price of 50 pence per Ordinary Share for a period of five years, conditional on either the market capitalisation of the Company exceeding US$250m for a period of three consecutive trading days or a future funding round being concluded with a post-money valuation of US$250m or greater (the "Warrants").
The Subscription is made by a private equity professional based in New York City. This investment is part of a larger investment related to his family's Family Office which is anticipated to subscribe to a further US$2.025m on the same terms, for which the documentation is currently in process (the "Additional Subscriptions").
The funds to be received will be used for the continuing development of the Company's artificial intelligence platform and regulatory licensing build alongside general working capital purposes.
The Subscription and Additional Subscription are all expected to complete and funds received during March 2022, at which point an update announcement will be made.
Richard Shearer, Tintra CEO, said, "I am extremely pleased to have on board this new partner and investor. One that shares our artificial intelligence driven vision of revolutionising how emerging markets directly benefit from financial inclusion. The family have deep private equity experience and those insights have already started to assist in our thinking. I know this is something that I will draw on, and will add value for the board and shareholders, over the coming months and years as we build out our game changing model."
Not sure what you mean by old news. As it’s a new Rns from this morning. Yes the agreement was put in place November 2020 but it’s also worth noting the price they were happy to receive the first lot of shares at.
1st dec 2020
Further to the announcement dated 9 November 2020, IQ-AI announces the allotment of 282,460 of ordinary shares in IQ-AI to Mayo Clinic at 13.21p per ordinary share (the "New Ordinary Shares"). The New Ordinary Shares were issued in accordance with the research and collaboration agreement regarding IB Trax between Mayo Clinic and Imaging Biometrics, LLC ("IB"), a subsidiary of IQ-AI.
It’s positive and shows the agreement is still in place from a couple of years ago.
9th Nov 2020
Under the terms of the Agreement, IQ-AI will issue Mayo Clinic a token of $50,000 of shares in IQ-AI at a price equivalent to the three-month average share price prior to the effective date of the Agreement. In addition, IQ-AI will issue the Mayo Clinic, $10,000 of shares in IQ-AI at a price equivalent to the three-month average share price prior to the date the shares are issued, on the first anniversary and every successive year whilst the agreement is in existence. In addition, the Mayo Clinic will receive a 4% on-going royalty on each sale of IB Trax, including $20,000 on the initial commercial installation.
Ultimately, the aim is to leverage IB's existing quantitative solutions and AI expertise to develop a streamlined workflow that systematically identifies, tracks, and reports changes to brain lesions. Currently, the way clinicians perform this task is cumbersome and subjective. The Mayo Clinic is ideally positioned to assist in this effort as it is renowned for excellence and commonly treats the most challenging of brain tumour cases from around the world.
It’s the first of $10,000 worth from the historical agreement very positive sign things are progressing and the Mayo clinic are happy to accept shares instead of cash imo.
Issue of shares to Mayo Clinic
Further to the Company's announcement dated 9 November 2020, IQ-AI announces the allotment of 113,781 ordinary shares of 1p each in IQ-AI (the "New Ordinary Shares") to Mayo Clinic, at a price of 6.41p per share. The New Ordinary Shares were issued in accordance with the research and collaboration agreement regarding IB Trax, entered into between Mayo Clinic and Imaging Biometrics, LLC, a subsidiary of IQ-AI.
Application will be made for the 113,781 New Ordinary Shares to be admitted to the Official List of the UK Listing Authority by way of a Standard Listing ("Admission") and it is expected that Admission will become effective and that dealing in the New Ordinary Shares will commence on or around 8 am on 11 February 2022. The New Ordinary Shares will rank pari passu with the existing ordinary shares of the Company.
Following Admission, the Company will have 182,621,390 ordinary shares of 1p each in issue, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 182,621,390.
The above figure of 182,621,390 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
@IQAI_IB
's IB Neuro quantitative DSC perfusion platform has been chosen by the Manchester Cancer Research Centre for a multi-year study. In the US, IB Neuro is the only MR perfusion platform used in multi-center clinical trials.
https://twitter.com/IQAI_IB/status/1481715877766701058
https://twitter.com/IQAI_IB/status/1478831521523900417
Imaging Biometrics is dedicated to creating the future! Our IB Zero G™ Technology provides contrast enhanced images without the growing health, and environmental concerns of gadolinium-based contrast agents! Advancing technology in pediatric imaging and kidney disease!
A Phase I trial of approximately 20 patients will be conducted at the Medical College of Wisconsin (MCW) to evaluate the safety and efficacy of Gallium Maltolate (GaM) in the treatment of Glioblastoma Multiforme (GBM). The trial, funded by IQ-AI, Ltd., was developed in part based on the results of a preclinical study led by medical oncologist Christopher Chitambar, MD, Emeritus Professor of Medicine and Biophysics, Division of Hematology and Oncology at MCW.
In the preclinical study, treatment with oral GaM caused a dramatic inhibition of tumor growth that was matched by a significant increase in overall survival. Dr. Christopher Chitambar’s group has shown that GaM kills cancer cells by “hijacking” iron metabolism. Essentially, the cancer cells are tricked into consuming GaM instead of iron, starving the tumor and ******ing cancer growth.
GaM is a metal-based compound with anticancer activity that can be administered orally. In prior FDA-approved Phase 1 clinical trials, oral GaM demonstrated low toxicity and was well tolerated. Lawrence R. Bernstein, PhD, is a co-investigator on the trial and will serve as the expert regarding the drug substance and formulations. He will also facilitate sourcing of the clinical-quality GaM. Dr. Chitambar and his colleague, Jennifer Connelly, MD, Associate Professor of Neurology, will be the co-principal investigators of the trial, which marks the first time an oral form of GaM will be used in GBM patients.
The neuro imaging platform of Imaging Biometrics, LLC (IB), a wholly owned subsidiary of IQAI, will be used to quantitively monitor tumor volumes. The FDA cleared IB Neuro™ and Delta T1™ maps have been used extensively in multi-center clinical trials to assess the efficacy for an array of brain tumor treatments.
If the outcomes look promising, IQAI will enlist a team of regulatory experts in attempt to accelerate the time to market, such as the Orphan Drug program, to benefit patients and their families. “We are taking this one step at a time and need to let the trial progress,” said Michael Schmainda, CEO of IB. “We are working with an excellent team of scientists and clinicians, and everyone is eager to move this study forward.”
GBM is the most common and aggressive primary brain cancer, with limited treatment options and a dismal prognosis. Current treatment involves maximal surgical resection followed by radiation therapy and chemotherapy (bevacizumab and temozolomide). The median survival of patients is only around 14 months. Despite decades of research, only incremental gains have been made to extend or enhance the quality of life.
https://www.appliedradiology.com/articles/phase-i-trial-to-evaluate-safety-efficacy-of-gallium-maltolate-for-glioblastoma-multiforme
Here’s the latest instalment in our news updates from Blackford Platform Partners.
Visualization and analytical solutions developer Imaging Biometrics highlighted a new paper in which IB Neuro, the company’s MR dynamic susceptibility contrast (DSC) perfusion platform, demonstrated clinical application throughout all phases of brain tumor management.
https://academic.oup.com/neurosurgeryopen/article/2/4/okab029/6370918
Neurosurgery Open, Volume 2, Issue 4, December 2021
ABSTRACT
BACKGROUND AND IMPORTANCE
Distinction of brain tumor progression from treatment effect on postcontrast magnetic resonance imaging (MRI) is an ongoing challenge in the management of brain tumor patients. A newly emerging MRI biomarker called fractional tumor burden (FTB) has demonstrated the ability to spatially distinguish high-grade brain tumor from treatment effect with important implications for surgical management and pathological diagnosis.
CLINICAL PRESENTATION
A 58-yr-old male with glioblastoma was treated with standard concurrent chemoradiotherapy (CRT) after initial resection. Throughout follow-up imaging, the distinction of tumor progression from treatment effect was of concern. The surgical report from a redo resection indicated recurrent glioblastoma, while the tissue sent for pathological diagnosis revealed no tumor. Presurgical FTB maps confirmed the spatial variation of tumor and treatment effect within the contrast-agent enhancing lesion. Unresected lesion, shown to be an active tumor on FTB, was the site of substantial tumor growth postresection.
CONCLUSION
This case report introduces the idea that a newly developed MRI biomarker, FTB, can provide information of tremendous benefit for surgical management, pathological diagnosis as well as subsequent treatment management decisions in high-grade glioma.
Iqai tweet!
https://twitter.com/IQAI_IB/status/1476300541735190535